Announcements Trials

Browse Landscape

Phase

Status

Completed 14 Withdrawn 1 Recruiting 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Urothelial Cancer 1

Interventions

pembrolizumab 65 Nivolumab 58 Magnetic Resonance Spectroscopy 53 enzalutamide 39 Abiraterone Acetate 37 Radiosurgery 36 Gemcitabine 35 Specimen Handling 32 Radiotherapy 32 Ipilimumab 32 Androgen Antagonists 32 Prednisone 31 apalutamide 28 Cisplatin 28 Docetaxel 27 Leuprolide 26 atezolizumab 25 Carboplatin 25 durvalumab 23 cabozantinib 23 darolutamide 20 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 19 olaparib 18 Goserelin 17 Radiation 16 Gonadotropin-Releasing Hormone 16 Biopsy 16 gallium 68 PSMA-11 15 Pluvicto 15 avelumab 14

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × vinflunine × Genitourinary × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡